Sanofi to Lay Off 229 Blueprint Medicines Employees and Close Cambridge Offices

Sanofi will lay off 229 employees from Blueprint Medicines in Massachusetts following its $9.1 billion acquisition of the Cambridge-based biotech, according to records the company filed with the state. The workforce reduction is part of a post-acquisition integration led by Sanofi, which is consolidating its footprint in the Boston area and closing legacy office sites.

Sanofi WARN Notice Details Layoffs and Office Closures

The job cuts affecting the Blueprint Medicines workforce will occur between Oct. 9, 2026, and late June 2027, according to a filing with the state’s Executive Office of Labor and Workforce Development, cited by STAT. According to Fierce Pharma, the workforce reduction represents the first major workforce reduction disclosed under new CEO Belén Garijo. Alongside the headcount cuts, Sanofi is shuttering two legacy Blueprint sites, including the biotech’s former global headquarters located at 45 Sidney St., as reported by the Boston Business Journal. Remaining Blueprint staff will report to Sanofi’s Cambridge Crossing campus, which opened in 2022 after the French drugmaker consolidated multiple nearby facilities.

Blueprint Medicines counted 682 full-time employees as of April 15, 2025, according to its last quarterly report filed before Sanofi announced the buyout in June 2025. The French pharmaceutical giant officially closed the $9.1 billion transaction in July 2025 to secure rare immunology drug Ayvakit alongside other KIT inhibitor pipeline candidates. Several former Blueprint senior leaders departed prior to the mass layoffs. Former CEO Kate Haviland became board chair at Cambridge-based GC Therapeutics at the turn of 2025, while former chief scientific officer Percy Carter joined Pfizer to lead preclinical and translational sciences. Additionally, former chief commercial officer Philina Lee became CEO of AdvanCell at the beginning of 2026.

Corporate Context and Post-Acquisition Strategy

A Sanofi spokesperson told Fierce Pharma that the planned changes are part of thoughtful organizational decisions to align the company structure with long-term business priorities, commercial portfolios, and pipeline demands. The spokesperson added that affected employees have already been informed and that the company will provide multiple avenues of support through their transitions. Post-acquisition consolidations represent a standard playbook for eliminating redundancies and cutting costs across the pharmaceutical sector.

The latest cuts at Blueprint may also foreshadow a wider corporate overhaul under Garijo, who assumed the role of CEO on May 1, 2026, succeeding Paul Hudson. During her first earnings call on July 30, 2026, Garijo stated that she must fully acknowledge the challenges confronting Sanofi and act with a sense of urgency to drive mid- and long-term growth. Other major pharmaceutical companies have similarly pursued cost-savings initiatives under new leadership, mirroring broader industry trends toward portfolio simplification and supply chain restructuring.